Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: An overview

被引:23
作者
Bailie, GR
Massry, SG
机构
[1] Albany Coll Pharm, Dept Pharm Practice, Albany Nephrol Pharm Grp, Albany, NY 12208 USA
[2] Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, Los Angeles, CA USA
来源
PHARMACOTHERAPY | 2005年 / 25卷 / 12期
关键词
nephrology clinical practice guidelines; chronic kidney disease; CKD; bone metabolism; bone disease; Kidney Disease Outcomes Quality Initiative; K/DOQI; National Kidney Foundation;
D O I
10.1592/phco.2005.25.12.1687
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The National Kidney Foundation developed and oversees the Kidney Disease Outcomes Quality Initiative, a process that develops clinical practice guidelines in nephrology Recent guidelines address the aberrations in bone metabolism and disease that occur as a complication of chronic kidney disease. These guidelines provide, for the first time, a standard approach to the detection and management of alterations in calcium, phosphorus, and parathyroid hormone metabolism. The problems and sequelae of soft-tissue calcification are discussed, and recommendations are provided for reducing the associated morbidity and mortality.
引用
收藏
页码:1687 / 1707
页数:21
相关论文
共 14 条
[1]   Clinical practice guidelines in nephrology: Evaluation, classification, and stratification of chronic kidney disease [J].
Bailie, GR ;
Uhlig, K ;
Levey, AS .
PHARMACOTHERAPY, 2005, 25 (04) :491-502
[2]   From dialysis outcomes quality initiative to kidney disease outcomes quality initiative: New clinical practice guidelines in nephrology - What the practicing pharmacist needs to know [J].
Bailie, GR .
PHARMACOTHERAPY, 2004, 24 (05) :551-557
[3]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[4]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[5]   DEFEROXAMINE THERAPY AND MUCORMYCOSIS IN DIALYSIS PATIENTS - REPORT OF AN INTERNATIONAL REGISTRY [J].
BOELAERT, JR ;
FENVES, AZ ;
COBURN, JW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1991, 18 (06) :660-667
[6]   MEDICATION KNOWLEDGE AND COMPLIANCE AMONG PATIENTS RECEIVING LONG-TERM DIALYSIS [J].
CLEARY, DJ ;
MATZKE, GR ;
ALEXANDER, ACM ;
JOY, MS .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1995, 52 (17) :1895-1900
[7]  
Cozzolino M, 2001, J AM SOC NEPHROL, V12, P2511, DOI 10.1681/ASN.V12112511
[8]   On the evolving nature of understanding dialysis-related disorders [J].
Eknoyan, G ;
Lindberg, JS .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) :S1-S3
[9]  
FORGET D, 1990, CONTRIB NEPHROL, V81, P79
[10]   Vascular calcification in chronic kidney disease [J].
Goodman, WG ;
London, G ;
Amann, K ;
Block, GA ;
Giachelli, C ;
Hruska, KA ;
Ketteler, M ;
Levin, A ;
Massy, Z ;
McCarron, DA ;
Raggi, P ;
Shanahan, CM ;
Yorioka, N .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (03) :572-579